W. P. O'meara, J. N. Mangeni, R. Steketee, and B. Greenwood, Changes in the burden of malaria in sub-Saharan Africa, Lancet Infect Dis, vol.10, issue.10, pp.70096-70103, 2010.

, World Health Organization. World malaria report, 2016.

A. M. Dondorp, F. Nosten, P. Yi, D. Das, A. P. Phyo et al., Artemisinin resistance in Plasmodium falciparum malaria, N Engl J Med, vol.361, pp.455-67, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02427334

W. E. Harrington, T. K. Mutabingwa, E. Kabyemela, M. Fried, and P. E. Duffy, Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance, Clin Infect Dis, vol.53, pp.224-254, 2011.

D. H. Hamer, M. Ndhlovu, D. Zurovac, M. Fox, K. Yeboah-antwi et al., Improved diagnostic testing and malaria treatment practices in Zambia, JAMA, vol.297, pp.2227-2258, 2007.

H. Noedl, Y. Se, K. Schaecher, B. L. Smith, D. Socheat et al.,

, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia, N Engl J Med, vol.359, pp.2619-2639, 2008.

, World Health Organization. Artemisinin and artemisinin-based combination therapy resistance. Status report, p.2017, 2017.

F. Ariey, B. Witkowski, C. Amaratunga, J. Beghain, A. C. Langlois et al., A molecular marker of artemisinin-resistant Plasmodium falciparum malaria, Nature, vol.505, pp.50-55, 2014.
URL : https://hal.archives-ouvertes.fr/pasteur-00921203

E. A. Ashley, M. Dhorda, R. M. Fairhurst, C. Amaratunga, P. Lim et al., Spread of artemisinin resistance in Plasmodium falciparum malaria, N Engl J Med, vol.371, pp.411-434, 2014.

B. Witkowski, V. Duru, N. Khim, L. S. Ross, B. Saintpierre et al., A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study, Lancet Infect Dis, vol.17, issue.16, pp.30415-30422, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01400955

R. Amato, P. Lim, O. Miotto, C. Amaratunga, D. Dek et al., Genetic markers associated with dihydroartemisininpiperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study, Lancet Infect Dis, vol.17, issue.16, pp.30409-30410, 2017.

S. K. Dhingra, D. Redhi, J. M. Combrinck, T. Yeo, J. Okombo et al., A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine, MBio, vol.8, pp.303-320, 2017.

A. B. Sidhu, A. C. Uhlemann, S. G. Valderramos, J. C. Valderramos, S. Krishna et al., Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin, J Infect Dis, vol.194, pp.528-563, 2006.

R. N. Price, A. C. Uhlemann, A. Brockman, R. Mcgready, A. E. Phaipun et al., Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number, Lancet, vol.364, pp.16767-16773, 2004.

P. Lim, A. P. Alker, N. Khim, N. K. Shah, S. Incardona et al., Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia

, Malar J, vol.8, p.11, 2009.

R. N. Price, C. Cassar, A. Brockman, M. Duraisingh, M. Van-vugt et al., The pfmdr1 gene is associated with a multidrugresistant phenotype in Plasmodium falciparum from the western border of Thailand, Antimicrob Agents Chemother, vol.43, pp.2943-2952, 1999.

C. M. Wilson, S. K. Volkman, S. Thaithong, R. K. Martin, D. E. Kyle et al., Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand, Mol Biochem Parasitol, vol.57, pp.151-60, 1993.

J. P. Gil and K. S. Pfmdr1, Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies, Expert Rev Anti Infect Ther, vol.15, pp.527-570, 2017.

E. Kamugisha, S. Jing, M. Minde, J. Kataraihya, G. Kongola et al., Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania, Malar J, vol.11, p.58, 2012.

C. Dokomajilar, S. L. Nsobya, B. Greenhouse, P. J. Rosenthal, and G. Dorsey, Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic, Antimicrob Agents Chemother, vol.50, pp.1893-1898, 2006.

M. T. Duraisingh and A. F. Cowman, Contribution of the pfmdr1 gene to antimalarial drug-resistance, Acta Trop, vol.94, pp.181-90, 2005.

D. A. Fidock, T. Nomura, A. K. Talley, R. A. Cooper, S. M. Dzekunov et al., Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance, Mol Cell, vol.6, pp.861-71, 2000.

O. A. Folarin, C. Bustamante, G. O. Gbotosho, A. Sowunmi, M. G. Zalis et al., In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria, Acta Trop, vol.120, pp.224-254, 2011.

J. M. Sá, O. Twu, K. Hayton, S. Reyes, M. P. Fay et al., Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine, Proc Natl Acad Sci U S A, vol.106, pp.18883-18892, 2009.

C. Sisowath, I. Petersen, M. I. Veiga, A. Mårtensson, Z. Premji et al., In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa, J Infect Dis, vol.199, pp.750-757, 2009.

O. Miotto, R. Amato, E. A. Ashley, B. Macinnis, J. Almagro-garcia et al., Genetic architecture of artemisinin-resistant Plasmodium falciparum, Nat Genet, vol.47, pp.226-260, 2015.

J. G. Kublin, F. K. Dzinjalamala, D. D. Kamwendo, E. M. Malkin, J. F. Cortese et al., Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria, J Infect Dis, vol.185, pp.380-388, 2002.

, Policy recommendation on intermittent preventive treatment during infancy with sulfadoxinepyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. Geneva: The Organization, pp.1-3

I. Petersen, R. Eastman, and M. Lanzer, Drug-resistant malaria: molecular mechanisms and implications for public health, FEBS Lett, vol.585, pp.1551-62, 2011.

I. M. Hastings and W. M. Watkins, Intensity of malaria transmission and the evolution of drug resistance, Acta Trop, vol.94, pp.218-247, 2005.

D. P. Kwiatkowski, How malaria has affected the human genome and what human genetics can teach us about malaria, Am J Hum Genet, vol.77, pp.171-92, 2005.

R. Ataide, E. A. Ashley, R. Powell, J. A. Chan, M. J. Malloy et al., Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort, Proc Natl Acad Sci U S A, vol.114, pp.3515-3535, 2017.

S. Enosse, P. Magnussen, F. Abacassamo, X. Gómez-olivé, A. M. Rønn et al., Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulfadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique, Malar J, vol.7, p.115, 2008.

J. Raman, K. Mauff, P. Muianga, A. Mussa, R. Maharaj et al., Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out, PLoS One, vol.6, issue.25992, 2011.

B. Galatas, L. Nhamussua, B. Candrinho, L. Mabote, P. Cisteró et al., In-vivo efficacy of chloroquine to clear asymptomatic infections in Mozambican adults: a randomized, placebo-controlled trial with implications for elimination strategies, Sci Rep, vol.7, p.1356, 2017.

A. Mayor, E. Serra-casas, A. Bardají, S. Sanz, L. Puyol et al., Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women

, Malar J, vol.8, issue.9, 2009.

S. M. Taylor, A. Mayor, G. Mombo-ngoma, H. M. Kenguele, S. Ouédraogo et al., A quality control program within a clinical trial consortium for PCR protocols to detect Plasmodium species, J Clin Microbiol, vol.52, pp.2144-2153, 2014.

D. Ménard, N. Khim, J. Beghain, A. A. Adegnika, M. Shafiul-alam et al., A worldwide map of Plasmodium falciparum K13-propeller polymorphisms, N Engl J Med, vol.374, pp.2453-64, 2016.

C. Salvador, B. Rafael, F. Matsinhe, B. Candrinho, R. Muthemba et al., Efficacy and safety of artemetherlumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, Acta Trop, vol.171, pp.146-50, 2015.

, Emerging Infectious Diseases ? www.cdc.gov/eid ?, vol.24, issue.1, 2018.

E. Kamau, S. Campino, L. Amenga-etego, E. Drury, D. Ishengoma et al., K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa, J Infect Dis, vol.211, pp.1352-1357, 2015.

V. Andriantsoanirina, A. Ratsimbasoa, C. Bouchier, M. Jahevitra, S. Rabearimanana et al., Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility, Antimicrob Agents Chemother, vol.53, pp.4588-97, 2009.
URL : https://hal.archives-ouvertes.fr/pasteur-00741124

R. Leang, W. R. Taylor, D. M. Bouth, L. Song, J. Tarning et al., Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment, Antimicrob Agents Chemother, vol.59, pp.4719-4745, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02560651

B. Q. Phuc, C. Rasmussen, T. T. Duong, L. T. Dong, M. A. Loi et al., Treatment failure of dihydroartemisinin/ piperaquine for Plasmodium falciparum malaria, Vietnam. Emerg Infect Dis, vol.23, pp.715-722, 2017.

M. B. Denis, R. Tsuyuoka, Y. Poravuth, T. S. Narann, S. Seila et al., Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia, Trop Med Int Health, vol.11, pp.1360-1366, 2006.

R. Leang, A. Barrette, D. M. Bouth, D. Menard, R. Abdur et al., Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, Antimicrob Agents Chemother, vol.57, pp.686-698, 2008.

C. Amaratunga, P. Lim, S. Suon, S. Sreng, S. Mao et al., Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study, Lancet Infect Dis, vol.16, pp.487-496, 2016.

S. Chaorattanakawee, C. Lon, K. Jongsakul, J. Gawee, S. Sok et al., Ex vivo piperaquine resistance developed rapidly in Plasmodium falciparum isolates in northern Cambodia compared to Thailand, Malar J, vol.15, p.519, 2016.

C. Escobar, S. Pateira, E. Lobo, L. Lobo, R. Teodosio et al., Polymorphisms in Plasmodium falciparum K13-propeller in Angola and Mozambique after the introduction of the ACTs, PLoS One, vol.10, p.119215, 2015.

, World Health Organization. Status report on artemisinin and ACT resistance, 2015.

R. Isozumi, H. Uemura, I. Kimata, Y. Ichinose, J. Logedi et al., Novel mutations in K13 propeller gene of artemisininresistant Plasmodium falciparum, Emerg Infect Dis, vol.21, pp.490-492, 2015.